Registration - Consultant

Subject Matters

• Aboriginal Affairs
• Agriculture
• Arts and Culture
• Broadcasting
• Constitutional Issues
• Consumer Issues
• Defence
• Education
• Employment and Training
• Energy
• Environment
• Fisheries
• Forestry
• Government Procurement
• Health
• Immigration
• Industry
• Infrastructure
• Intellectual Property
• Internal Trade
• International Relations
• International Trade
• Justice and Law Enforcement
• Labour
• Mining
• Regional Development
• Science and Technology
• Small Business
• Sports
• Taxation and Finance
• Telecommunications
• Tourism
• Transportation

Subject Matter Details

Legislative Proposal, Bill or Resolution

• Canada's Food and Consumer Safety Action Plan as it relates to the regulation and protection of biopharmaceutical products
• Health Canada’s Interim Orders relating to COVID-19: The Interim Order Respecting Drugs, Medical Devices and Foods for a Special Dietary Purpose in Relation to COVID-19; The Interim Order Respecting Clinical Trials for Medical Devices and Drugs Relating to COVID-19; The Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19; The Interim Order Respecting the Prevention and Alleviation of Shortages of Drugs in Relation to Covid-19
• Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
• Proposed pharmacare legislation related to any future national pharmacare program

Legislative Proposal, Bill or Resolution, Regulation

• Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies
• Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals

Policies or Program

• Anti-Counterfeit Trade Agreement (ACTA) as it concerns counterfeit drugs
• Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease
• Canada-United States Regulatory Cooperation Council (RCC) initiatives related to the regulation of biopharmaceutical products
• Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships
• Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework
• Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH)
• Free trade treaty agreement as they relate to the North American Free Trade Agreement (NAFTA) and free trade negotiations as it relates to India, the European Union, Japan, MERCOSUR and the Trans-Pacific Partnership
• Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
• Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits
• Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations
• The government's Science and Technology strategy as it relates to the biopharmaceutical industry
• World Health Organization (WHO) issues concerning pharmaceuticals as it relates to Counterfeits, Access to Medicines, and the Intergovernmental Working Group (IGWG) World Intellectual Property Organization (WIPO) issues concerning the protection of and access to intellectual property
• World Trade Organization (WTO) issues concerning the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility"

Regulation

• Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products
• Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry
• New Substances Notification Regulations as it relates to the biopharmaceutical industry
• Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
• Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive
• Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products
• Smart Regulations as it relates to the biopharmaceutical industry

Communication Techniques

• Written communication
• Oral communication

The lobbyist has arranged or expects to arrange one or more meetings on behalf of the client between a public office holder and any other person in the course of this undertaking.

Government Institutions

• Agriculture and Agri-Food Canada (AAFC)
• Canada Revenue Agency (CRA)
• Canadian Institutes of Health Research (CIHR)
• Canadian International Trade Tribunal (CITT)
• Canadian Tourism Commission (CTC)
• Employment and Social Development Canada (ESDC)
• Environment and Climate Change Canada (ECCC)
• Fisheries and Oceans Canada (DFO)
• Global Affairs Canada (GAC)
• Health Canada (HC)
• Innovation, Science and Economic Development Canada (ISED)
• Justice Canada (JC)
• National Research Council (NRC)
• Natural Resources Canada (NRCan)
• Natural Sciences and Engineering Research Council (NSERC)
• Patented Medicine Prices Review Board (PMPRB)
• Prime Minister's Office (PMO)
• Privy Council Office (PCO)
• Public Health Agency of Canada (PHAC)
• Public Services and Procurement Canada (PSPC)
• Senate of Canada
• Statistics Canada (StatCan)
• Treasury Board Of Canada Secretariat (TBS)
• Veterans Affairs Canada (VAC)

Address:
55 Metcalfe St.
Suite 1220
Ottawa, ON  K1P 6L5
Canada

Telephone number: 613-236-0455

Client representative

David Renwick, Interim President

Parent Company Information

Innovative Medicines Canada / Médicaments novateurs Canada is not a subsidiary of any other parent companies.

Business address:
95 St. Clair Avenue West
Suite 1606
Toronto, ON  M4V 1N6
Canada

Telephone number: 416-920-0716